secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001193125-24-001933
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma announces 2024 strategic priorities; Phase 3 readouts in 3Q/4Q 2024
--------------------------------------------------------------------------------

- Expects topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024.
- Expects topline data from Phase 3 BROADWAY trial in ASCVD in 4Q 2024.
- Plans to initiate TANDEM Phase 3 FDC trial in 1Q 2024; topline data in 1Q 2025.
- Completes enrollment in PREVAIL CVOT in 1Q 2024; topline data in 2026.
- Cash sufficient to fund operations through 2026, beyond three Phase 3 readouts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524001933/0001193125-24-001933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524001933/d822244d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-001933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer